Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Blueprint Medicines Corpo...

    NASDAQ: BPMC · Real-Time Price · USD
    101.46
    1.12 (1.12%)
    At close: May 23, 2025, 3:59 PM
    104.00
    2.50%
    After-hours: May 23, 2025, 05:08 PM EDT
    1.12%
    Bid 89
    Market Cap 6.55B
    Revenue (ttm) 562.12M
    Net Income (ttm) -155.73M
    EPS (ttm) -2.51
    PE Ratio (ttm) -40.42
    Forward PE 99.44
    Analyst Buy
    Ask 115
    Volume 247,569
    Avg. Volume (20D) 977,055
    Open 99.14
    Previous Close 100.34
    Day's Range 98.56 - 101.69
    52-Week Range 73.04 - 121.90
    Beta 0.83

    About BPMC

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol BPMC
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for BPMC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 weeks ago
    +10.89%
    Blueprint Medicines shares are trading higher afte... Unlock content with Pro Subscription
    3 months ago
    -8.08%
    Blueprint Medicines shares are trading lower after company reported worse-than-expected Q4 EPS results.
    news image

    5 days ago · businesswire.com

    VantAI Expands Strategic Collaboration with Blueprint Medicines to Advance Induced Proximity Drug Discovery

    NEW YORK--(BUSINESS WIRE)-- #AI--VantAI, a leader in generative AI and proximity-based therapeutics, announced today that it has entered into a second expansion of its collaboration and license agreem...

    news image

    3 weeks ago · zacks.com

    Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

    BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.

    news image

    3 weeks ago · seekingalpha.com

    Blueprint Medicines Corporation (BPMC) Q1 2025 Earnings Call Transcript

    Blueprint Medicines Corporation (NASDAQ:BPMC ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Jenna Cohen - Vice President, Investor Relations & Global Business Communica...

    news image

    3 weeks ago · zacks.com

    Blueprint Medicines (BPMC) Reports Q1 Loss, Lags Revenue Estimates

    Blueprint Medicines (BPMC) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $1.32 per share a year ago.

    news image

    1 month ago · zacks.com

    Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy?

    Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    news image

    1 month ago · seekingalpha.com

    Blueprint Medicines Continues Targeting Mast Cells For Potential Billion-Dollar Growth

    Blueprint Medicines' focus on Ayvakit continues to pay off, which has ample untapped revenue potential in advanced and indolent systemic mastocytosis. Additionally, their pipeline includes other promi...

    Add to Watchlist